General Nutraceutical Technology, LLC.

GNT was co-founded by Dr. Xiu-Min Li with the goal to translate laboratory discoveries to the real world.

GNT has developed an internal therapeutics pipeline and has established a network of business affiliates.

GNT works closely with academic researchers investigating potential treatment for allergic diseases, cancer, and infectious diseases.

GNT received financial support from private Foundations for R&D.

GNT contracts with academic institutions. 

GNT received NIH/NIAID R21 grant (Title: IgE Suppressing Berberine Nanomedicine for Treatment of Peanut and Tree nut Allergies) in 2023.

GNT received NIH/NIAID R44 SBIR Phase II grant (Title: IgE Suppressing Berberine Nanomedicine for Treatment of Food Allergies) in 2023.

GNT received NIH/NIAID R41 STTR Phase I grant (Title: IgE-suppressing small molecule compound Xanthopurpurin analog for multiple food allergies) in 2023.

GNT provides support for clinical research of botanical medicines and developing advanced new medicines.

GNT maintains partnership with other companies.